Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Cancer

Malaisrie, S. Christopher; Untch, Brian R.; Aranha, Gerard V.; Mohideen, Najeeb; Hantel, Alexander; Pickleman, Jack

doi:10.1001/archsurg.139.5.532

Cited by 38 publications

(29 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Curative surgery of the esophagus is usually performed for lesions of the gastroesophageal junction and the middle or lower third of the thoracic esophagus. Radiationtherapy and chemotherapy may be added [11][12][13][14][15]. Surgery for the squamous cell carcinoma of the cervical esophagus is very extensive and cause major functional impairments and high morbidity and mortality rates.…”

Section: Introductionmentioning

confidence: 99%

Clinical characteristics and outcome of patients with stage III esophageal carcinoma: a single-center experience from Turkey

et al. 2007

View full text Add to dashboard Cite

Esophageal carcinoma is an extremely deadly disease, and prognosis is poor. We retrospectively evaluated stage III esophageal carcinoma patients in our center. Median age of the patients was 52. Men to women ratio were 3/1. Epidermoid carcinoma was the major histology. Incidence of esophageal carcinoma was higher in the distal and middle third of the esophagus. In 19 patients tumor size was more than 5 cm. In total of 17 of the patients were operated. About 58 patients were irradiated. About 45 of the patients were irradiated with curative intent, 31 of them were primarily irradiated and 14 of them were irradiated postoperatively. Only 13 of the patients received concurrent chemoradiotherapy. Overall 1, 2, 3, and 4 year survival rates were 38.9%, 11.1%, 5.6%, and %1.9, respectively and median survival was 12 months. Median survival for tumors located in cervical esophageal, middle esophagus, and distal esophagus were 23, 8, and 14 months, respectively. One, 2, 3, 4 year survival rates of operated patients were 58.8%, 29.4%, 17.6%, 5.9%, respectively and median survival was 23 months. For inoperable patients 1 and 2 year survival rates were 29.7% and 2.7% and median survival was 8 months. Differences between operable and inoperable patients were statistically significant (P: 0.0003). One, 2, 3, 4 years survival results of patients treated with surgery and postoperative radiotherapy was 62.5%, 25%, 12.5%, 12.5% and median survival was 21 months, 1, 2, 3, 4 years survival results of patients treated with surgery and concurrent chemoradiotherapy was 55.6%, 33.3%, 22.2%, and 0% and median survival was 27 months. There was no statistically significant difference between groups (P: 0.5390). During the therapy, disphagia was the major side effect observed in seven patients. Fatigue, pain, and mild weight loss were the other side effects. Three patients could not tolerate the treatment and left the therapy. We demonstrated that stage III esophageal carcinoma is an extremely deadly disease, and in spite of major advances in cancer treatment, prognosis is still poor.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical characteristics and outcome of patients with stage III esophageal carcinoma: a single-center experience from Turkey

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Alguns trabalhos avaliando o tratamento neo-adjuvante foram publicados com resultados controversos especialmente em relação à possível melhora da sobrevida as custas de maiores complicações peri-operatórias 1,2,4,8,11,14,15,16,17,18,19,21,22,28,35,36,38,40 .…”

Section: Discussionunclassified

Terapêutica neo-adjuvante aumenta as complicações pós-operatórias da esofagectomia?

Tercioti

Lopes

Coelho-Neto

et al. 2010

ABCD, arq. bras. cir. dig.

View full text Add to dashboard Cite

RESUMO -Racional -O câncer de esôfago é o oitavo tipo de câncer mais incidente na população no mundo, sendo que no Brasil são estimados 10.630 novos casos para o ano de 2010. Na terapêutica curativa, a esofagectomia destaca-se nas suas mais diversas modalidades de tratamento. Objetivo -Avaliar por meio de um estudo retrospectivo não-randomizado as complicações peri-operatórias dos pacientes submetidos à esofagectomia por carcinoma epidermóide do esôfago, com ou sem terapêutica neoadjuvante.

show abstract

“…В настоящее время комплексный метод лечения больных с местно-распространенным раком пищевода находит все большее число сторонников, что подтверж-дается результатами ряда исследований [1,4], и рекомен-дован в странах Европы и США [3,7].…”

Section: In the Treatment Of Many Unresolved Issues Indicating The Nunclassified

Analysis results of combined treatment of patients with verified cancer of the cervical esophagus and hypopharynx with the application of surgical treatment with one-stage defect’s plastic

Раджабова¹,

Левченко²,

Dunaevskiĭ³

et al. 2016

Opuholi golovy šei

View full text Add to dashboard Cite

Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Cancer

Abstract: Hypothesis: Patients receiving neoadjuvant chemoradiotherapy followed by surgery (CRS) undergo downstaging of their tumor and have improved survival when compared with patients undergoing surgery followed by adjuvant chemoradiotherapy (SCR).

Cited by 38 publications

References 41 publications

Clinical characteristics and outcome of patients with stage III esophageal carcinoma: a single-center experience from Turkey

Clinical characteristics and outcome of patients with stage III esophageal carcinoma: a single-center experience from Turkey

Terapêutica neo-adjuvante aumenta as complicações pós-operatórias da esofagectomia?

Analysis results of combined treatment of patients with verified cancer of the cervical esophagus and hypopharynx with the application of surgical treatment with one-stage defect’s plastic

Contact Info

Product

Resources

About